SCHEMBL7006943

SCHEMBL7006943

COc1ccccc1Cn1cnc2nn(C)cc2c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.50
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 2/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
PKM P14618 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
RXFP1 Q9HBX9 2/20 0.43
MAPT P10636 2/20 0.43
SIRT2 Q8IXJ6 2/20 0.42
HTT P42858 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
YTHDC1 Q96MU7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7004068 0.84 SMN1; SMN2 (0.62) TP53POLBLMNAKMT2AMEN1
SCHEMBL7079144 0.83 SMN1; SMN2 (0.45) PDE5ATP53POLBLMNAKMT2A
SCHEMBL7000340 0.83 ALDH1A1 (0.50) TP53KMT2AMEN1GAASMN1; SMN2
SCHEMBL7003807 0.82 PDE5A (0.51) PDE5ATP53POLBTDP1LMNA
SCHEMBL7000103 0.81 ALDH1A1 (0.53) TP53POLBTDP1LMNASMN1; SMN2
SCHEMBL7077435 0.80 ALDH1A1 (0.45) POLBLMNAKMT2AMEN1GAA
SCHEMBL7001724 0.80 TP53 (0.56) TP53LMNAKMT2APKMSMN1; SMN2
SCHEMBL7003827 0.80 SMN1; SMN2 (0.49) POLBLMNAGAASMN1; SMN2HPGD
SCHEMBL7081274 0.77 LMNA (0.51) LMNAKMT2AMEN1PKMGAA
SCHEMBL7000183 0.75 SMN1; SMN2 (0.51) LMNAKMT2AMEN1PKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US claimed
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US disclosed
EP-1311510-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ARZNEIMITTELWERK DRESDEN GMBH (DE) 2003-05-21 EP disclosed
WO-2002018387-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ELBION AG (DE) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same DDO, GRIN3A, GRIK4 PDE5A 1318/4885TP53 4374/4885POLB 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.